Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
ASH, the world's
largest professional society concerned with the causes and treatments of blood
disorders, regularly issues press releases highlighting clinical and research
advances announced at the ASH annual meeting and published
in Blood, as well as releases and statements on breaking policy news
affecting the field of hematology.
Need to speak with an expert? Complete our Request An Expert form.
To be added to ASH's press release distribution list, contact Amanda Szabo at email@example.com.
Recognizing that leukemia cannot be conquered with a “one-size-fits-all”
approach, researchers are pursuing novel targeted therapies and combinations of
existing treatment regimens with new agents for patient populations with
historically poor prognoses, according to data presented today during the 56th
American Society of Hematology Annual Meeting and Exposition.
Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments
for blood clots and further illuminate clot risks in vulnerable populations,
such as cancer patients.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research.
Support the mission of ASH and help move hematology forward.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology